Austen Ng

Principal Scientist at Intellia Therapeutics - Cambridge, MA, US

Austen Ng's Colleagues at Intellia Therapeutics
James Basta

Executive Vice President, General Counsel and Corporate Secretary

Contact James Basta

Kathleen Shea

Sr. Executive Assistant to the CEO at Intellia Therapeutics

Contact Kathleen Shea

Michelle Ryan

Senior Contracts Manager

Contact Michelle Ryan

Brittany DiCredico

Manager, Talent Acquisition Operations

Contact Brittany DiCredico

Aayush Pandey

Senior Project Manager, CMC (Technical Operations)

Contact Aayush Pandey

Wanda Paul

Accounts Payable Specialist

Contact Wanda Paul

View All Austen Ng's Colleagues
Austen Ng's Contact Details
HQ
857-285-6200
Location
Greater Boston
Company
Intellia Therapeutics
Austen Ng's Company Details
Intellia Therapeutics logo, Intellia Therapeutics contact details

Intellia Therapeutics

Cambridge, MA, US • 500 - 999 Employees
BioTech/Drugs

Intellia Therapeutics is a leading genome editing company whose mission is to develop potentially curative gene editing treatments that can positively transform the lives of people living with severe and life-threatening diseases.We are focused on the development of proprietary therapeutics using a recently developed biological tool known as the CRISPR/Cas9 system. The promise of the CRISPR/Cas9 system is the driving force behind the creation of Intellia. Our founders have a shared belief that the CRISPR/Cas9 technology has the potential to transform medicine by permanently editing disease-associated genes in the human body with a single treatment course. This technology offers the potential for us to develop curative therapeutic options for patients with chronic diseases by addressing the underlying cause of the disease. It can bring new hope and cures to people who now have nowhere to turn for help.Our combination of deep scientific expertise and clinical development experience, along with our leading intellectual property portfolio, puts Intellia in a unique position to unlock broad therapeutic applications of the CRISPR/Cas9 technology and create a new class of therapeutic products. Intellia has the right people, assets and ambitious vision needed to take full advantage of the CRISPR/Cas9 technology's attributes – high potency, specificity, simplicity of use, broad applicability, and multifunctional programmability – and accelerate the advancement of curative products into the clinic.View our social media community guidelines at https://www.intelliatx.com/terms-and-conditions/ .

B2C Biotechnology Cleantech Healthcare Medical Diagnostics Pharmaceuticals Wind Power Biotech BioTech/Drugs Commercial Physical Research Biotech Pharmaceuticals
Details about Intellia Therapeutics
Frequently Asked Questions about Austen Ng
Austen Ng currently works for Intellia Therapeutics.
Austen Ng's role at Intellia Therapeutics is Principal Scientist.
Austen Ng's email address is ***@intelliatx.com. To view Austen Ng's full email address, please signup to ConnectPlex.
Austen Ng works in the BioTech/Drugs industry.
Austen Ng's colleagues at Intellia Therapeutics are James Basta, Kathleen Shea, Chantel Boucher, Michelle Ryan, Brittany DiCredico, Aayush Pandey, Wanda Paul and others.
Austen Ng's phone number is 857-285-6200
See more information about Austen Ng